In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
All content for GFN News is the property of GFN.TV and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
GFN.TV Interviews | HARM IS HARM | Breaking Down the WHO’s Ideological Wall
GFN News
28 minutes 50 seconds
2 weeks ago
GFN.TV Interviews | HARM IS HARM | Breaking Down the WHO’s Ideological Wall
The World Health Organization is no longer just fighting smoking—it’s waging an ideological war against nicotine itself. In this blistering interview, former WHO official Professor Tikki Pang exposes how the global health establishment has become evidence-blind, influenced by Bloomberg funding, and driven by a moral crusade that erases the distinction between smoking and safer alternatives. From “harm is harm” rhetoric to regulatory capture, Pang warns that WHO’s stance is fueling misinformation, stifling science, and putting millions of lives at risk.
Featuring:
PROF. TIKKI PANG
Former Director, Research, Policy & Cooperation
World Health Organization, Geneva, Switzerland
GFN News
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
